BioTime and Subsidiary LifeMap Sciences Announce the Launch of LifeMap BioReagents™ Portal ALAMEDA, Calif.--(BUSINESS WIRE)--Nov. 14, 2012--
BioTime, Inc. (NYSE MKT: BTX) and its subsidiary LifeMap Sciences have
announced the launch of LifeMap BioReagents™ (http://bioreagents.lifemapsc.com/),
a new portal offering researchers access to BioTime’s research product
lines including PureStem™ human progenitor cell lines, PureStem™
packages, clinical and research grade human embryonic stem cell lines
(hES), HyStem® hydrogels, culture media, and
cell differentiation kits.
LifeMap Sciences will be the principle marketing and sales arm for
BioTime’s cell-based products and related reagents for the research
community in academia, research hospitals, and biotech and pharma
companies. LifeMap Sciences holds the exclusive, worldwide license to
market GeneCards® (www.genecards.org),
with over 12 million page visits per year from hundreds of thousands of
unique users worldwide, and MalaCards (www.malacards.org),
and plans to launch LifeMap Discovery™, its database for
biomedical and stem cell research, later this quarter.
LifeMap BioReagents™ is integrated with the GeneCards®,
MalaCards, and LifeMap Discovery™ databases, thereby
providing a large number of biomedical researchers accessing these
databases a means of identifying stem cell reagents that can enhance
research and discovery efforts in a variety of fields, including stem
cell research, developmental biology, mechanisms of various human
diseases, drug discovery and therapeutic discovery and development.
“There has been growing interest in the PureStem and hES cell lines,”
stated Yaron Guan-Golan, Head of Marketing at LifeMap Sciences. “Our
ability to provide stable, characterized, pure, and scalable cell lines
to the research community and to industry is a big step forward—not only
in the study of stem cells, but also in the understanding of cellular
and developmental biology and human disease, and in the discovery of new
therapies. Together with our LifeMap Discovery™ database,
researchers will now be able to immediately obtain access to
cutting-edge embryonic stem and progenitor cell lines as part of a
wealth of developmental and stem cell information that they need for
research.”
About LifeMap Sciences, Inc.
LifeMap Sciences’ (www.lifemapsc.com)
core technology and business is based on its integrated database suite,
the discovery platform for biomedical and stem cell research. This
platform includes GeneCards®, the leading human
gene database; LifeMap Discovery™, the database of embryonic
development, stem cell research, and regenerative medicine; and MalaCards,
the human disease database. LifeMap Sciences also markets PanDaTox,
an innovative, recently developed, searchable database that can aid in
the discovery of new antibiotics and biotechnologically beneficial
products.
In addition to database offerings, LifeMap Sciences is BioTime’s
principal marketing subsidiary for research products, including PureStem™
human progenitor cell lines, GMP human embryonic stem (hES) cell lines, ESpan™
growth media for progenitor cell lines, and cell differentiation media
for non-therapeutic uses, via its LifeMap BioReagents™ portal.
LifeMap Sciences will utilize its databases as part of its online
marketing strategy to reach life sciences researchers at biotech and
pharmaceutical companies and at academic institutions and research
hospitals worldwide.
In a therapeutic discovery collaboration with BioTime, LifeMap’s
scientists utilize LifeMap’s proprietary platform, including LifeMap
Discovery™, its stem cell database along with the GeneCards®
and MalaCards integrated database suite, to aid in the
development of BioTime’s proprietary PureStem™ human progenitor
cell lines into products for the treatment of human diseases, especially
degenerative diseases that might be treatable with cell replacement
therapies. The LifeMap Discovery™ platform will be used to select
the progenitor cell lines that are most likely to facilitate the
development of cell-based regenerative medicine therapies for a wide
range of diseases.
About BioTime, Inc.
BioTime, headquartered in Alameda, California, is a biotechnology
company focused on regenerative medicine and blood plasma volume
expanders. Its broad platform of stem cell technologies is enhanced
through subsidiaries focused on specific fields of application. BioTime
develops and markets research products in the fields of stem cells and
regenerative medicine, including a wide array of proprietary PureStem™
cell lines, HyStem® hydrogels, culture media, and
differentiation kits. BioTime is developing Renevia™ (formerly
known as HyStem®-Rx), a biocompatible,
implantable hyaluronan and collagen-based matrix for cell delivery in
human clinical applications. BioTime's therapeutic product development
strategy is pursued through subsidiaries that focus on specific organ
systems and related diseases for which there is a high unmet medical
need. BioTime's majority owned subsidiary Cell Cure Neurosciences Ltd.
is developing therapeutic products derived from stem cells for the
treatment of retinal and neural degenerative diseases. BioTime's
subsidiary OrthoCyte Corporation is developing therapeutic applications
of stem cells to treat orthopedic diseases and injuries. Another
subsidiary, OncoCyte Corporation, focuses on the diagnostic and
therapeutic applications of stem cell technology in cancer, including
the diagnostic product PanC-Dx™ currently being developed for the
detection of cancer in blood samples. ReCyte Therapeutics, Inc. is
developing applications of BioTime's proprietary induced pluripotent
stem cell technology to reverse the developmental aging of human cells
to treat cardiovascular and blood cell diseases. BioTime's subsidiary
LifeMap Sciences, Inc. markets GeneCards®, the leading
human gene database, and is developing an integrated database suite to
complement GeneCards® that will also include the LifeMap™
database of embryonic development, stem cell research and regenerative
medicine, and MalaCards, the human disease database. LifeMap will
also market BioTime research products. BioTime's lead product, Hextend®,
is a blood plasma volume expander manufactured and distributed in the
U.S. by Hospira, Inc. and in South Korea by CJ CheilJedang Corporation
under exclusive licensing agreements. Additional information about
BioTime can be found on the web at www.biotimeinc.com.
Forward-Looking Statements
Statements pertaining to future financial and/or operating results,
future growth in research, technology, clinical development, and
potential opportunities for BioTime and its subsidiaries, along with
other statements about the future expectations, beliefs, goals, plans,
or prospects expressed by management constitute forward-looking
statements. Any statements that are not historical fact (including, but
not limited to statements that contain words such as "will," "believes,"
"plans," "anticipates," "expects," "estimates") should also be
considered to be forward-looking statements. Forward-looking statements
involve risks and uncertainties, including, without limitation, risks
inherent in the development and/or commercialization of potential
products, uncertainty in the results of clinical trials or regulatory
approvals, need and ability to obtain future capital, and maintenance of
intellectual property rights. Actual results may differ materially from
the results anticipated in these forward-looking statements and as such
should be evaluated together with the many uncertainties that affect the
business of BioTime and its subsidiaries, particularly those mentioned
in the cautionary statements found in BioTime's Securities and Exchange
Commission filings. BioTime disclaims any intent or obligation to update
these forward-looking statements.
To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list: http://phx.corporate-ir.net/phoenix.zhtml?c=83805&p=irol-alerts
Source: BioTime, Inc.
BioTime, Inc.
Peter Garcia, 510-521-3390, ext 367
Chief
Financial Officer
pgarcia@biotimemail.com
or
Judith
Segall, 510-521-3390, ext 301
jsegall@biotimemail.com
or
LifeMap
Sciences, Inc.
Kenneth Elsner, 781-826-7719
COO
ke@lifemapsc.com
View printer-friendly version